世界の小分子がん治療薬市場(~2026):投与量・価格・臨床試験インサイト

◆英語タイトル:Global Small Molecule Cancer Drug Market, Drug Price, Dosage and Clinical Trials Insight 2026
◆商品コード:KUIK21FB012
◆発行会社(リサーチ会社):Kuick Research
◆発行日:2020年6月
◆ページ数:753
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single userUSD3,300 ⇒換算¥376,200見積依頼/購入/質問フォーム
Multi UserUSD6,000 ⇒換算¥684,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はKuick Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Kuick Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

本市場調査レポートでは、世界の小分子がん治療薬市場について調査・分析を行い、イントロダクション、小​​分子薬の必要性、がん小分子薬と他の利用可能な治療法との比較、新たながん治療薬としての小分子薬物、市場動向・機会、臨床パイプラインの概要、小分子がん治療薬の研究分析、パートナーシップ分析・コラボレーション、未来洞察、新型コロナウイルス感染症の影響、小分子薬の可用性・投与量・価格分析、競争状況などを掲載しています。
・イントロダクション
・小​​分子薬の必要性
・がん小分子薬と他の利用可能な治療法との比較
・新たながん治療薬としての小分子薬物
・市場動向・機会
・臨床パイプラインの概要
・小分子がん治療薬の研究分析
・パートナーシップ分析・コラボレーション
・未来洞察
・新型コロナウイルス感染症の影響
・乳がん用小分子薬:可用性・投与量・価格分析
・白血病がん用小分子薬:可用性・投与量・価格分析
・肺がん用小分子薬:可用性・投与量・価格分析
・リンパ腫用小分子薬:可用性・投与量・価格分析
・骨髄腫用小分子薬:可用性・投与量・価格分析
・前立腺がん用小分子薬:可用性・投与量・価格分析
・競争状況
【レポートの概要】

“Global Small Molecule Cancer Drug Market, Drug Price, Dosage and Clinical Trials Insight 2026″ Report Highlights:

Small Molecule Cancer Drug Market Opportunity: More Than US$ 125 Billion by 2026
USA Dominates The Global Small Molecule Cancer Drug Market: >50% Share
Small Molecule Cancer Drug Market Clinical Trials: >2500 Drugs
Small Molecule Cancer Drugs Dosage, Sales, Price and Patent Insight: 175 Drugs
Small Molecule Drug Insight by Cancer
Clinical Trials Insight by Phase, Company, Country, Formulation, Indication
Covid-19 Impact On Small Molecule Cancer Drug Market

The small molecule drug centric approach has transformed the global cancer therapy market and has helped to decrease the mortality rate by overcoming the drawbacks of the traditional therapies such as chemotherapy, radiation therapy and others. The fundamental approach of using big molecular based drugs for the cancer treatment has now been shifted towards to small molecule drugs driven by multiple advantages over traditional or large molecules based drugs. The arrival of small molecule drugs in the cancer therapeutics landscape is not less than a massive breakthrough. From different radiation waves to immune cells, all have got settled in the cancer therapeutics market but the advent of small molecule drugs is however an accomplishment that is greater than any other major discovery in the cancer therapeutics market.

“Small Molecule Cancer Drug Market To Double In Next 6 Year Period To US$ 130 Billion Driven By New Drug Launches and Dynamic Clinical Pipeline”

An important parameter that should be associated with any of the cancer treatment is its specificity. Being specific to the cancer target is one of the most requisite and fundamental premise that decides whether the cancer therapy will result in inclination or declination of the mortality rate. The small molecule drug approach is quite specific and target oriented in functionality and has achieved interest of all stake holders from global cancer therapy market. The basic approach is to search for a specific molecular target and undergo the elimination of the cancer cells from the body. The small molecule cancer drug methodology is conceptually more specific than any of the available traditional non-targeted therapy as it provides a better target specificity and better reach to the cancer cells.

Other than all the commercially available cancer treatments, small molecule drugs are on the urge to provide a treatment strategy that has more success rate for overall survival. Many parameters are associated with the small molecule drugs that have made them quite promising for the use. Some of the parameters include: molecular size, availability, site of action, cell permeability and mode of administration. All of these factors are somehow responsible for the success that small molecule drugs have achieved in short period of time.

“Small Molecule Based Cancer Drugs Account For More Than 25% Of The Global Cancer Drug Pipeline”

As of now, small molecule drugs are considered as a special cancer therapy due to the advantages that are associated with it. In today’s cancer therapeutics world, there are two therapies that undergo specific molecular targeting: monoclonal antibody and small molecule drugs. But there is also one parameter that is making small molecule drugs more preferable than the monoclonal antibodies is the size of small molecule drugs making it permeable to plasma membrane or cell membrane. From the different studies that have been performed under the cancer research domain, it has been confirmed that in case of different cancer types, there are receptors for target that are present inside the cell membrane. The presence of target inside the cell membrane makes it difficult for other drugs to penetrate or target the desired receptor. At this position, the usage of small molecule drugs is necessary as it has the ability to cross the cell membrane due to small size and target the cancer receptor that is present inside the cell membrane.

The small molecule drugs have the ability to target different mechanisms through which cancer develops and grows. An important mechanism through cancer is developed is by controlling all the growth factors required for the growth and development of the cells. As it has been well-studied that there are certain growth factors that are responsible for different mechanisms in the body and by controlling the mechanism of growth factor, cancer can easily surpass all the factors that can lead to its eradication.

The future market scenario looks promising for the research, development and commercial viability of small molecule based cancer drugs. The basic targeting advantage along with the dominance of small molecule drugs in cancer clinical pipeline will drive the global small molecule cancer drug market in coming years. The market is expected to double its revenue to US$ 130 Billion by 2026 and will continue to outperform the others available drug therapies for the treatment of cancer malignancies.

【レポートの目次】

1. Introduction to Small Drug Molecule

2. Need for Small Molecule Drug

3. Comparison of Cancer Small Molecule Drugs with Other Available Therapies
3.1 Small Molecule Cancer Drugs and its Comparison with Other Drugs Parameters
3.2 Small Molecule Cancer Drug vs. Immunotherapy
3.3 Small Molecule Cancer Drugs vs. Chemotherapy
3.4 Small Molecule Cancer Drug vs. Radiation Therapy
3.5 Small Molecule Cancer Drugs vs. Surgical Removal of Cancer Cells

4. Small Drug Molecule as Emerging Cancer Therapeutics
4.1 Small Molecule Drugs and its Relation with Cancer Treatment
4.2 Mechanisms Targeted by Small Molecule Drugs in Cancer Therapy
4.2.1 Small Molecule Drugs as Growth Factor Kinase Inhibitor for Cancer Therapy
4.2.2 Small Molecule Drugs as DNA Damage Response Inhibitors for Cancer Therapy
4.3 Small Molecule Inhibitors and their Related Pathways

5. Global Trends and Opportunities for Small Molecule Cancer Drug Market
5.1 US
5.2 Europe
5.3 Asia
5.4 Rest of World

6. Global Small Molecule Cancer Drug Clinical Pipeline Overview
6.1 By Phase
6.2 By Formulation
6.3 By Company
6.4 By Country
6.5 By Indication
6.6 By Mechanism of Action

7. Global Analysis for Small Molecule Cancer Drug Research Work at Educational Level
7.1 IACS-10759 Small Molecule Drug Discovery at MD Anderson
7.2 BET Small Molecule Inhibitor Discovery by Yale Researchers for the Cancer
Patients
7.3 Amgen and Mirati’s Small Molecule Cancer Drug against KRAS Gene in Different
Cancer Types
7.4 AOH1160 Small Molecule Research to Focus Breast Cancer at University of
California

8. Global Analysis for Partnerships, Collaborations for Expanding Small Molecule Cancer Drug Market
8.1 IACS and X-Chem to Undergo Small Molecule Cancer Therapies Development
8.2 MD Anderson, Artios Pharma and ShangPharma to Collaborate for Small Molecule
ATR Inhibitor Program
8.3 Aptose Biosciences and Moffitt Cancer Center to Undergo Strategic Collaboration for
the Development of New Multi-Targeting Epigenetic Therapeutic Agents
8.4 Merck and Taiho to Collaborate for Small KRAS- Targeting Cancer Drugs

9. Drivers and Challenges Associated with the Small Molecule Cancer Drug Market
9.1 Potential Insights about Factors Driving the Small Molecule Cancer Drug Market at
Global Level
9.2 Challenges Concerning the Growth of Small Molecule Cancer Drug Market

10. Future Insights for Small Molecule Cancer Market in Cancer Research Area

11. Covid-19 Impact On Small Molecule Cancer Drug Market

12. Small Molecule Drugs for Breast Cancer – Availability, Dosage and Price Analysis
12.1 Ribociclib (Kisqali)
12.2 Alpelisib (Piqray)
12.3 Abemaciclib (Verzenio)
12.4 Talazoparib (Telzenna)
12.5 Nertinib (Nerlynx)
12.6 Palbociclib (Ibrance)
12.7 Ixabepilone (Ixempra)
Anastrazole (Arimidex)
12.8 Lapatinib (Tykerb)
12.9 Toremifene (Fareston)
12.10 Letrozole (Femara)
12.11 Raloxifene (Evista)
12.12 Tamoxifen Oral Liquid (Soltamax)
12.13 Exemestane (Aromasin)
12.14 Testosterone Cypionate (Depo-Testosterone)
12.15 Fluoxymesterone (Halotestine/Androxy)
12.16 Fadrozole (Afema)
12.17 Tamibarotene (Amnolake)
12.18 Testosterone Propionate

13. Small Molecule Drugs for Leukemia Cancer – Availability, Dosage and Price Analysis
13.1 Gilteritinib (Xospata)
13.2 Venetoclax (Venclexta)
13.3 Bosutinib (Bosulif)
13.4 Nilotinib (Tasigna)
13.5 Tretinoin (Vesanoid)
13.6 Clofarabine (Clolar)
13.7 Cytarabine/Daunorubicin (Vyxeos)
13.8 Dasatinib (Sprycel)
13.9 Ponatinib (Iclusig)
13.10 Enasidenib (Idhifa)
13.11 Ivosidenib (Tibsovo)
13.12 Cladribine (Mavenclad/Leustatin)
13.13 Mercaptopurine Oral Suspension (Purixan)
13.14 Methotrexate Oral Solution (Xatmep)
13.15 Pentostatin (Nipent)
13.16 Arsenic Trioxide (Trisenox)
13.17 Quizartinib (Vanflyta)
13.18 Histamine Dihydrochloride Injection (Ceplene)
13.19 Ubenimix (Bestatin)
13.20 Omacetaxine Mepesuccinate (Synribo)
13.21 Radotinib (Supect)

14. Small Molecule Drugs for Lung Cancer – Availability, Dosage and Price Analysis
14.1 Gefitinib (Irresa)
14.2 Entrectinib (Rozlytrek)
14.3 Osimertinib (Tagrisso)
14.4 Erlotinib (Tarceva)
14.5 Brigatinib (Alunbirg)
14.6 Lorbrena (Lorlatinib)
14.7 Vinorelbine (Navelbine)
14.8 Zykadia (Certinib)
14.9 Pemetrexed (Alimta)
14.10 Alectinib (Alecensa)
14.11 Xalkori (Crizotinib)
14.12 Nintedanib (Ofev)
14.13 Anlotinib (Focus V)
14.14 Amrubicin (Calsed)
14.15 Icotinib (Conmana)

15. Small Molecule Drugs for Lymphomas – Availability, Dosage and Price Analysis
15.1 Copanlisib (Aliqopa)
15.2 Methoxsalen Solution (Uvadex)
15.3 Pralatrexate (Folotyn)
15.4 Bexarotene Topical (Targretin Gel)
15.5 Pixantrone (Pixuvri)
15.6 Belinostat (Beleodaq)
15.7 Zanubrutinib (Brukinsa)
15.8 Vorinostat (Zolinza)
15.9 Romidepsin (Istodax)
15.10 Bexarotene (Targretin)
15.11 Mechlorethamine (Valchlor/Ledaga)

16. Small Molecule Drugs for Myeloma – Availability, Dosage and Price Analysis
16.1 Ixazomib (Ninlaro)
16.2 Melphalan Intravenous (Evomela/Chemostat)
16.3 Thalidomide (Thalomid)
16.4 Selinexor (Xpovio)
16.5 Panobinostat (Farydak)
16.6 Bortezomib (Velcade)
16.7 Pomalidomide (Pomalyst)
16.8 Dexamethasone High Dose (Neofordex)

17. Small Molecule Drugs for Prostate Cancer – Availability, Dosage and Price Analysis
17.1 Xtandi (Enzalutamide)
17.2 Apalutamide (Erleada)
17.3 Ertafitinib (Balversa)
17.4 Darolutamide (Nubeqa)
17.5 Bicalutamide (Casodex)
17.6 Nilutamide (Nilandron)
17.7 Abiraterone (Zytiga)
17.8 Xofigo (Radium Ra 223 dichloride)
17.9 Pedeliporfin (Tookad)

18. Small Molecule Drugs for Gastric Cancer – Availability, Dosage and Price Analysis
18.1 Avapritinib (Ayvakit)
18.2 Rivoceranib (Aitan)
18.3 Gimeracil/Oteracil/Tegafur (Teysuno/TS-1)
18.4 Eptaplatin/Heptaplatin

19. Small Molecular Drugs For Cancer Diagnosis – Availability, Dosage and Price Analysis
19.1 Fluciclovine 18F (Axumin)
19.2 Tc 99m Tilmanocept (Lymphoseek)
19.3 Perflubutane (Sonazoid)
19.4 Hexyl Aminolevulinate (Cysview)
19.5 Fluorocholine 18F (IASOcholine/Pcolina)
19.6 Gadobuterol (Gadavist)

20. Small Molecule Drugs for Skin Cancer – Availability, Dosage and Price Analysis
20.1 Benimetinib (Mektovi)
20.2 Cobimetinib (Cotellic)
20.3 Sonidegib (Odomzo)
20.4 Vismodegib (Erivedge)
20.5 Imiquimod (Aldara/Zyclara)
20.6 Amivolevulinic Acid (Ameluz)
20.7 Methyl Aminolevulinate (Metvixia/Metvix PDT)
20.8 Vemurafenib (Zelboraf)

21. Small Molecule Drugs for Pancreatic Cancer – Availability, Dosage and Price Analysis
21.1 Irinotecan Liposome Injection (Onivyde)

22. Small Molecule Drugs for Thyroid Tumors – Availability, Dosage and Price Analysis
22.1 Vendetanib (Caprelsa)

23. Small Molecule Drugs for Renal Cancer – Availability, Dosage and Price Analysis
23.1 Axitinib (Inlyta)

24. Small Molecule Drugs for Colorectum Cancer – Availability, Dosage and Price Analysis
24.1 Tipiracil/Trifluridine (Lonsurf)
24.2 Irinotecan (Camptosar)
24.3 Oxaliplatin (Eloxatin)
24.4 Raltitrexed (Tomudex)
24.5 Irinotecan-Eluting Beads (Paragon Beads/Debiri)
24.6 Fruquintinib (Elunate)

25. Small Molecule Drugs for Solid Tumors – Availability, Dosage and Price Analysis
25.1 Larotectinib (Viktravi)

26. Small Molecule Drugs Targeting Multiple Cancer – Availability, Dosage, Price and Sales Analysis
26.1 Fludarabin (Fludara/Oforta)
26.2 Gemcitabine (Gemzar)
26.3 Sorafnib (Nexavar)
26.4 Rucaparib (Rubraca)
26.5 Doxorubicin (Aridamycin)
26.6 Acalabrutinib (Calquence)
26.7 Ibrutinib (Imbruvica)
26.8 Azacitidine (Vidaza)
26.9 Lenalidomide (Revlimid)
26.10 Doxorubicin Liposomal (Doxil)
26.11 Tazemetostat (Tazverik)
26.12 Busulfan (Busulfex)
26.13 Afatinib (Gilotrif)
26.14 Gemcitabine (Infugem)
26.15 Carmustine Polifeprosan 20 wafer (Gliadel)
26.16 Eribulin (Halaven)
26.17 Paclitaxel-Protein Bound (Abraxane)
26.18 Trabectedine (Yondelis)
26.19 Paclitaxel (Taxol)
26.20 Docetaxel (Taxotere)
26.21 Idelalisib (Zydelig)
26.22 Duvelisib (Copiktra)
26.23 Regorafenib (Stivagra)
26.24 Nelarabine (Arranon)
26.25 Capecitabine (Xeloda)
26.26 Lenvatinib (Lenvima)
26.27 Olaparib (Lynparza)
26.28 Niraparib (Zejula)
26.29 Pazopanib (Votrient)
26.30 Alitretinoin Topical (Panretin)
26.31 Mitotane (Lysodren)
26.32 Valrubicin (Valstar)
26.33 Hydroxyurea (Hydrea)
26.34 Mitoxantrone (Novantrone)
26.35 Zoledronic Acid (Zometa/Reclast)
26.36 Fotemustine (Muforan)
26.37 Paclitaxel Nanoparticle (Nanoxel)
26.38 Topotecan (Hycamtin)
26.39 Decitabine (Decogen)
26.40 Tivozanib (Fotivda)
26.41 Telotristat Etiprate (Xermelo)
26.42 Imatinib (Gleevec)
26.43 Trametinib (Mekinist)
26.44 Cabozantinib (Cabometyx)
26.45 Encorafenib (Braftovi)
26.46 Dabrafenib (Tafinlar)
26.47 Sunintab (Sutent)
26.48 Levoleucovorin (Fusilev/Khapzory)
26.49 Bendamustine (Treanda/Belrapzo/Bendeka)
26.50 Forodesine (Fodosine/Mundesine)
26.51 Talaporfin (Laserphyrin)
26.52 Tucidinostat (Epidaza)
26.53 Doxorubicin Eluting Beads (DC Beads)
26.54 Temozolomide (Temodar)
26.55 Paclitaxel Polymeric Micelle Formulation (GenexolPM)
26.56 Docetaxel polymeric micelle (Nanoxel M)
26.57 Methotrexate
26.58 Treosulfan (Ovastat/Tercondi)
26.59 Belotecan (Camtobell)
26.60 Paclitaxel Liposomal(Lipusu/Bevetex)
26.61 Amsacrine (Amsa PD/Amekrin)
26.62 Cyclophosphamide
26.63 Docetaxel Nanosome (DoceAqualip)
26.64 Pamidronic acid (Aredia)
26.65 Mopidamol (Rapenton)
26.66 Nedaplatin (Aqupla)
26.67 Cytarabin/Cytarabin Liposomal (DepoCyt)
26.68 Dianhydrogalactitol (DAG for Injection)

27. Competitive Landscape
27.1 Johnson and Johnson
27.2 Teva Pharmaceutical
27.3 Boehringer Ingelheim
27.4 Allergan
27.5 Pfizer
27.6 Bristol-Myers Squibb
27.7 Merck
27.8 GlaxoSmithKline
27.9 AstraZeneca
27.10 Gilead Sciences



【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[世界の小分子がん治療薬市場(~2026):投与量・価格・臨床試験インサイト]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆